In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab ...

Please provide your email address to receive an email when new articles are posted on . Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate ...

Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis. A new review of the latest therapies for myasthenia gravis (MG), including ...

The use of a monoclonal antibody that reduced circulating IgG levels, led to a decrease in preexisting neutralizing antibodies (NAbs) to adeno-associated virus (AAV). The study, which showed that this ...

Myasthenia gravis is a lifelong (chronic) autoimmune condition, which means that the body’s immune system attacks its own healthy cells. Most people with generalized myasthenia gravis (gMG) have ...